<code id='C623DC3CD3'></code><style id='C623DC3CD3'></style>
    • <acronym id='C623DC3CD3'></acronym>
      <center id='C623DC3CD3'><center id='C623DC3CD3'><tfoot id='C623DC3CD3'></tfoot></center><abbr id='C623DC3CD3'><dir id='C623DC3CD3'><tfoot id='C623DC3CD3'></tfoot><noframes id='C623DC3CD3'>

    • <optgroup id='C623DC3CD3'><strike id='C623DC3CD3'><sup id='C623DC3CD3'></sup></strike><code id='C623DC3CD3'></code></optgroup>
        1. <b id='C623DC3CD3'><label id='C623DC3CD3'><select id='C623DC3CD3'><dt id='C623DC3CD3'><span id='C623DC3CD3'></span></dt></select></label></b><u id='C623DC3CD3'></u>
          <i id='C623DC3CD3'><strike id='C623DC3CD3'><tt id='C623DC3CD3'><pre id='C623DC3CD3'></pre></tt></strike></i>

          Home / entertainment / focus

          focus


          focus

          author:knowledge    Page View:983
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In